ST. LOUIS, MO – Avadel Pharmaceuticals, a dynamic biopharmaceutical company driven by a mission to transform medicines and improve lives, has placed Erin Sarin as their new Head of Total Rewards. Managing Partner, Ayla Maloney and Recruiting Director, Carrie Longmire led and placed the crucial search.
“Erin Sarin is the perfect fit for Avadel’s present and future state. Her total rewards leadership experience in large and small companies alike have built an incredibly well-rounded tool belt that she applies with agility to enable rapid growth. Erin is a genuine, fast-paced and stra-tactical leader. We wish her and the Avadel team much success as they continue to impact the health and well-being of their consumers,” shared Ayla Maloney, Managing Partner at TCG.
As the Head of Total Rewards, Erin Sarin will be a strategic, hands-on leader reporting to the Head of HR, collaborating with executive leadership to design and align rewards initiatives with Avadel’s core values and business objectives. In this role, she will have a significant impact on shaping the future of Avadel’s workforce by developing and overseeing comprehensive compensation and benefits strategies that support the mission. Erin will be responsible for designing competitive salary structures, managing incentive and equity programs, and ensuring all rewards strategies foster inclusivity, collaboration, and innovation. She’ll also be a trusted advisor on compensation matters, providing insights and recommendations based on market trends and industry best practices. In addition to compensation, Erin will oversee Avadel’s benefits programs, including health plans, retirement, and wellness initiatives. Her leadership will ensure these offerings meet the diverse needs of Avadel’s employees, utilizing data and analytics to assess program effectiveness, while reflecting their commitment to stewardship and well-being.
“I am truly excited to join the incredible team at Avadel Pharmaceuticals. I look forward to working alongside such talented individuals under strong leadership to support the company’s growth and evolution. Our collective focus on innovative solutions will not only help elevate Avadel’s workforce but will directly contribute to improving the lives of the patients we serve. I’m honored to play a part in shaping a rewarding, inclusive environment that drives both organizational success and meaningful impact in healthcare,” shared Erin Sarin.
Erin Sarin is an accomplished global rewards strategist and HR technology enthusiast with a passion for transforming work experiences. As the new Head of Total Rewards at Avadel Pharmaceuticals, Erin brings a wealth of expertise in employee benefits design, change management, and HR technology transformation. With leadership experience at companies like Lantheus, Moderna, and MITRE, she has successfully implemented innovative benefits programs, optimized compensation strategies, and integrated AI-driven HR solutions to enhance employee engagement and organizational efficiency. A dedicated advocate for inclusive workplace strategies, Erin also serves as Vice President of Administration at the New England Employee Benefits Council (NEEBC), where she contributes to shaping the future of employee rewards and benefits.
About Avadel Pharmaceuticals
Avadel Pharmaceuticals is a dynamic biopharmaceutical company driven by a mission to transform medicines and improve lives. They focus on innovative solutions that tackle the challenges patients face with current treatment options. One of the company’s key advancements is in the area of oxybate therapy, which is a widely used treatment for excessive daytime sleepiness (EDS) and cataplexy in individuals with narcolepsy. While traditional oxybate products require two nightly doses—one at bedtime and another in the middle of the night—Avadel has revolutionized this with their new therapy, LUMRYZ.
LUMRYZ, which received FDA approval on May 1, 2023, offers a once-nightly dose that eliminates the need for patients to wake up during the night for a second dose. This major improvement has earned LUMRYZ seven years of Orphan Drug Exclusivity from the FDA, and it is recognized as clinically superior to the previously available therapies.
What sets Avadel apart is its dedication to making a positive impact—not just for patients but also for their community and one another. Employees live the Avadel Values in everything they do, which is what makes working at Avadel a special experience.
About The Christopher Group
Through its award-winning, customized HR solutions, The Christopher Group (TCG) delivers critical human capital solutions in the area of executive HR search, interim HR leaders, fractional CHROs, and HR advisory and consulting. Since 1998, TCG has served clients across all industries, locations, company sizes, and verticals. Staffed by former HR professionals and highly trained search practitioners who have sat in the job, TCG has been named one of the Fastest-Growing, Best Non-Profit, Diversity, Private Equity, and Top 50 Executive Recruiting Firms by Hunt Scanlon as well as Forbes’ 2019, 2020, 2021 & 2022 list of America’s Best Executive Recruiting Firms.